Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as anecortave acetate
anecortave · 4 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Anecortave Acetate 30 | EXPERIMENTAL | - |
| Anecortave Acetate 15 | EXPERIMENTAL | - |
| Anecortave Acetate 3 | EXPERIMENTAL | - |
| Anecortave Acetate Vehicle | PLACEBO_COMPARATOR | - |
| 1 | ACTIVE_COMPARATOR | 50 mgs of anecortave acetate (0.5 ml of a 10% suspension) |
| 2 | ACTIVE_COMPARATOR | Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension) |
| 3 | ACTIVE_COMPARATOR | Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension) |
| 4 | ACTIVE_COMPARATOR | Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension) |
| Name | Type | Description |
|---|---|---|
| anecortave acetate | DRUG | - |
| Anecortave acetate 30 mg | DRUG | 0.5ml administered onto the sclera once every six months for 24 months |
| Anecortave Acetate 15 mg | DRUG | 0.5ml administered onto the sclera once every six months for 24 months |
| Anecortave Acetate 3 mg | DRUG | 0.5ml administered onto the sclera once every six months for 24 months |
| Anecortave Acetate Vehicle | OTHER | 0.5ml administered onto the sclera once every six months for 24 months |
Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE2 | Iptacopan, GT005, FWY003 |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Hoffmann-La Roche | RHHBY | 10 | PHASE3 | Ranibizumab, Susvimo, RO7965032, OpRegen, Faricimab |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Amgen Inc. | AMGN | 1 | PHASE3 | ABP 938, Aflibercept |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Ocugen Inc | OCGN | 1 | PHASE3 | OCU410 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-033 |
| Bayer | BAYRY | 2 | - | Aflibercept |
Anecortave is an investigational ophthalmology drug studied for age-related macular degeneration (AMD), including exudative AMD, and for posterior uveitis. Clinical trials have evaluated it in patients with subfoveal choroidal neovascularization due to exudative AMD and as prophylactic treatment in patients with a Retisert implant.
Anecortave is being developed by Alcon Inc., which trades under the ticker ALC. Alcon is an eye care company, and anecortave is part of its ophthalmology pipeline.
Anecortave is in Phase 2 development. It has been studied in completed Phase 1, Phase 2, and Phase 3 clinical trials, but it is not approved and remains investigational.
Anecortave has been studied in completed trials including NCT00570479, a Phase 1 study of prophylactic anecortave acetate in patients with a Retisert implant; NCT00346957, a Phase 2 study in exudative AMD; NCT00346866, a Phase 2 study versus placebo in AMD patients following PDT; and NCT00058994, a Phase 3 study in subfoveal CNV due to exudative AMD.
Yes, anecortave is also known as anecortave acetate, and it has been referred to as anecortave acetate 30 mg in some contexts. These names refer to the same investigational compound.